GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cidara Therapeutics Inc (NAS:CDTX) » Definitions » Cyclically Adjusted PB Ratio

Cidara Therapeutics (Cidara Therapeutics) Cyclically Adjusted PB Ratio : 0.24 (As of Jun. 09, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Cidara Therapeutics Cyclically Adjusted PB Ratio?

As of today (2024-06-09), Cidara Therapeutics's current share price is $12.84. Cidara Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $53.58. Cidara Therapeutics's Cyclically Adjusted PB Ratio for today is 0.24.

The historical rank and industry rank for Cidara Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

CDTX' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.21   Med: 0.27   Max: 0.43
Current: 0.24

During the past years, Cidara Therapeutics's highest Cyclically Adjusted PB Ratio was 0.43. The lowest was 0.21. And the median was 0.27.

CDTX's Cyclically Adjusted PB Ratio is ranked better than
80.33% of 661 companies
in the Biotechnology industry
Industry Median: 1.75 vs CDTX: 0.24

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Cidara Therapeutics's adjusted book value per share data for the three months ended in Mar. 2024 was $-3.898. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $53.58 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Cidara Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Cidara Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cidara Therapeutics Cyclically Adjusted PB Ratio Chart

Cidara Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 0.29

Cidara Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.35 0.29 0.34

Competitive Comparison of Cidara Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Cidara Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cidara Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cidara Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Cidara Therapeutics's Cyclically Adjusted PB Ratio falls into.



Cidara Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Cidara Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=12.84/53.58
=0.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cidara Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Cidara Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-3.898/131.7762*131.7762
=-3.898

Current CPI (Mar. 2024) = 131.7762.

Cidara Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 -18.032 99.070 -23.985
201503 -25.976 99.621 -34.360
201506 177.749 100.684 232.640
201509 164.462 100.392 215.877
201512 150.748 99.792 199.063
201603 137.398 100.470 180.210
201606 122.022 101.688 158.127
201609 106.230 101.861 137.428
201612 105.143 101.863 136.020
201703 90.437 102.862 115.858
201706 72.670 103.349 92.659
201709 59.971 104.136 75.889
201712 58.214 104.011 73.754
201803 47.611 105.290 59.588
201806 59.352 106.317 73.565
201809 50.399 106.507 62.357
201812 42.522 105.998 52.863
201903 32.927 107.251 40.457
201906 23.746 108.070 28.955
201909 29.668 108.329 36.089
201912 22.362 108.420 27.179
202003 26.505 108.902 32.072
202006 19.682 108.767 23.846
202009 13.453 109.815 16.143
202012 4.775 109.897 5.726
202103 0.784 111.754 0.924
202106 6.379 114.631 7.333
202109 -0.467 115.734 -0.532
202112 6.358 117.630 7.123
202203 1.436 121.301 1.560
202206 -2.300 125.017 -2.424
202209 2.548 125.227 2.681
202212 -3.985 125.222 -4.194
202303 5.962 127.348 6.169
202306 3.416 128.729 3.497
202309 1.778 129.860 1.804
202312 -1.812 129.419 -1.845
202403 -3.898 131.776 -3.898

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cidara Therapeutics  (NAS:CDTX) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Cidara Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Cidara Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cidara Therapeutics (Cidara Therapeutics) Business Description

Traded in Other Exchanges
Address
6310 Nancy Ridge Drive, Suite 101, San Diego, CA, USA, 92121
Cidara Therapeutics Inc is a biotechnology company. It is focused on the discovery, development, and commercialization of novel anti-infectives for the treatment and prevention of diseases. The company's Rezafungin is a novel molecule in the echinocandin class of antifungals. It is developing rezafungin for the first-line treatment and prevention of serious, invasive fungal infections which are associated with high mortality rates. Its other product candidates include CD377, CD388, RSV AVC, HIV AVC, and SARS-CoV-2 AVC.
Executives
Leslie Tari officer: Chief Scientific Officer C/O CIDARA THERAPEUTICS, INC., 6310 NANCY RIDGE DR SUITE 101, SAN DIEGO CA 92121
Taylor Sandison officer: Chief Medical Officer 6310 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Jeffrey Stein director, officer: President & CEO 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Shane Ward officer: CHIEF LEGAL OFFICER C/O VERSARTIS, INC., 4200 BOHANNON DR., SUITE 250, MENLO PARK CA 94025
Preetam Shah officer: CFO & CBO C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLR., NEW YORK NY 10019
Paul Daruwala officer: Chief Medical Officer 6310 NANCY RIDGE DR, SAN DIEGO CA 92121
Brady Johnson officer: Dir. of Finance & Controller 6310 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Timothy R Franson director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Carin Canale-theakston director C/O CIDARA THERAPEUTICS, INC., 6310 NANCY RIDGE DR STE 101 CA 92121
Bonnie L Bassler director REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
James E. Levine officer: Chief Financial Officer 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Theodore R Schroeder director 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Chrysa Mineo director 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
David L Gollaher director 6310 NANCY RIDGE DR, SAN DIEGO CA 92121
Daniel D Burgess director C/O HOLLIS-EDEN PHARMACEUTICALS, 4435 EASTGATE MALL STE.400, SAN DIEGO CA 92121

Cidara Therapeutics (Cidara Therapeutics) Headlines

From GuruFocus